ARCT vs. RCUS, LGND, STOK, NRIX, STTK, ALPN, ALKS, PRGO, CRNX, and RARE
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), Stoke Therapeutics (STOK), Nurix Therapeutics (NRIX), Shattuck Labs (STTK), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry.
Arcturus Therapeutics (NASDAQ:ARCT) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, Arcturus Therapeutics had 6 more articles in the media than Arcus Biosciences. MarketBeat recorded 12 mentions for Arcturus Therapeutics and 6 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.83 beat Arcturus Therapeutics' score of 0.69 indicating that Arcus Biosciences is being referred to more favorably in the news media.
Arcturus Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics has a net margin of -81.59% compared to Arcus Biosciences' net margin of -97.47%. Arcturus Therapeutics' return on equity of -37.61% beat Arcus Biosciences' return on equity.
Arcturus Therapeutics presently has a consensus target price of $64.86, suggesting a potential upside of 103.83%. Arcus Biosciences has a consensus target price of $40.50, suggesting a potential upside of 161.29%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Arcturus Therapeutics.
Arcturus Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Arcturus Therapeutics received 245 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 65.44% of users gave Arcturus Therapeutics an outperform vote while only 64.66% of users gave Arcus Biosciences an outperform vote.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 13.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 12.3% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Arcturus Therapeutics beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
